02.11.19

One-Year Results from Phase 3 Eylea Trial in Diabetic Retinopathy Presented

Source: Regeneron Pharmaceuticals

01.31.19

Ranibizumab and Aflibercept Prompt Comparable Visual Gain in AMD

Source: Reuters

10.27.18

Novartis: Two-Year Head-to-Head Data for Brolucizumab Reaffirm Superiority vs Aflibercept in Reducing Retinal Fluid in Patients With Wet AMD

Source: Novartis

10.25.18

Eylea Meets Main Goals in Phase 3 Non-Proliferative Diabetic Retinopathy Study

Source: Regeneron Pharmaceuticals

09.25.18

Novartis: New Analysis of Phase 3 Brolucizumab Data Reinforces Superior Reduction of Retinal Fluid

Source: Novartis

09.13.18

FDA to Review Eylea (Aflibercept) Injection for the Treatment of Diabetic Retinopathy

Source: Regeneron Pharmaceuticals

08.17.18

FDA Approves 12-Week Dosing for Eylea in Wet AMD Patients

Source: Regeneron Pharmaceuticals

08.14.18

Regeneron Faces Delay to FDA Approval of 12-Week Dosing Schedule for Eylea in Wet AMD

Source: FirstWord

07.11.18

Some AMD Patients May Not Respond to Intravitreal Aflibercept

Source: Reuters

View more stories